DBV Technologies(DBVT) - 2024 Q1 - Quarterly Results
DBV Technologies(DBVT)2024-05-08 04:39
Exhibit 99.1 Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update ● VITESSE enrollment on track to screen last patient by Q3 2024 ● Appointment of Robert Pietrusko, PharmD to Chief Regulatory Officer ● Q1 2024 closes with a cash balance of $101.5 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic c ...